These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

620 related articles for article (PubMed ID: 10824073)

  • 41. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron.
    Gralla R; Lichinitser M; Van Der Vegt S; Sleeboom H; Mezger J; Peschel C; Tonini G; Labianca R; Macciocchi A; Aapro M
    Ann Oncol; 2003 Oct; 14(10):1570-7. PubMed ID: 14504060
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Oral ondansetron for the control of cisplatin-induced delayed emesis: a large, multicenter, double-blind, randomized comparative trial of ondansetron versus placebo.
    Navari RM; Madajewicz S; Anderson N; Tchekmedyian NS; Whaley W; Garewal H; Beck TM; Chang AY; Greenberg B; Caldwell KC
    J Clin Oncol; 1995 Sep; 13(9):2408-16. PubMed ID: 7666101
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America.
    Poli-Bigelli S; Rodrigues-Pereira J; Carides AD; Julie Ma G; Eldridge K; Hipple A; Evans JK; Horgan KJ; Lawson F;
    Cancer; 2003 Jun; 97(12):3090-8. PubMed ID: 12784346
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparison of ondansetron and ondansetron plus dexamethasone as antiemetic prophylaxis during cisplatin-containing chemotherapy.
    Smith DB; Newlands ES; Rustin GJ; Begent RH; Howells N; McQuade B; Bagshawe KD
    Lancet; 1991 Aug; 338(8765):487-90. PubMed ID: 1714532
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Ondansetron plus metopimazine compared with ondansetron alone in patients receiving moderately emetogenic chemotherapy.
    Herrstedt J; Sigsgaard T; Boesgaard M; Jensen TP; Dombernowsky P
    N Engl J Med; 1993 Apr; 328(15):1076-80. PubMed ID: 8455664
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting over multiple cycles of moderately or highly emetogenic chemotherapy.
    Rapoport B; Schwartzberg L; Chasen M; Powers D; Arora S; Navari R; Schnadig I
    Eur J Cancer; 2016 Apr; 57():23-30. PubMed ID: 26851398
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Randomized double-blind crossover ondansetron-dexamethasone versus ondansetron-placebo study for the treatment of chemotherapy-induced nausea and vomiting in pediatric patients with malignancies.
    Alvarez O; Freeman A; Bedros A; Call SK; Volsch J; Kalbermatter O; Halverson J; Convy L; Cook L; Mick K
    J Pediatr Hematol Oncol; 1995 May; 17(2):145-50. PubMed ID: 7749764
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Difference in persistence of efficacy of two antiemetic regimens on acute emesis during cisplatin chemotherapy. The Italian Group for Antiemetic Research.
    J Clin Oncol; 1993 Dec; 11(12):2396-404. PubMed ID: 8246029
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Oral ondansetron for the control of delayed emesis after cisplatin. Report of a phase II study and a review of completed trials to manage delayed emesis.
    Kris MG; Tyson LB; Clark RA; Gralla RJ
    Cancer; 1992 Aug; 70(4 Suppl):1012-6. PubMed ID: 1386282
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Ondansetron for nausea and vomiting associated with moderately emetogenic cancer chemotherapy.
    DiBenedetto J; Cubeddu LX; Ryan T; Kish JA; Sciortino D; Beall C; Eisenberg PD; Henderson C; Griffin D; Wentz A
    Clin Ther; 1995; 17(6):1091-8. PubMed ID: 8750400
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Single-dose intravenous casopitant in combination with ondansetron and dexamethasone for the prevention of oxaliplatin-induced nausea and vomiting: a multicenter, randomized, double-blind, active-controlled, two arm, parallel group study.
    Hesketh PJ; Wright O; Rosati G; Russo M; Levin J; Lane S; Moiseyenko V; Dube P; Kopp M; Makhson A
    Support Care Cancer; 2012 Jul; 20(7):1471-8. PubMed ID: 21822913
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparison of dexamethasone and ondansetron in the prophylaxis of emesis induced by moderately emetogenic chemotherapy.
    Jones AL; Hill AS; Soukop M; Hutcheon AW; Cassidy J; Kaye SB; Sikora K; Carney DN; Cunningham D
    Lancet; 1991 Aug; 338(8765):483-7. PubMed ID: 1678453
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Phase II trial of ramosetron plus dexamethasone in the prevention of cisplatin-induced nausea and vomiting.
    Voravud N; Sriuranpong V
    J Med Assoc Thai; 2005 Dec; 88(12):1790-6. PubMed ID: 16518975
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Ondansetron plus dexamethasone compared to the 'standard' metoclopramide combination.
    Roila F
    Oncology; 1993; 50(3):163-7. PubMed ID: 8459986
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy.
    Aapro MS; Grunberg SM; Manikhas GM; Olivares G; Suarez T; Tjulandin SA; Bertoli LF; Yunus F; Morrica B; Lordick F; Macciocchi A
    Ann Oncol; 2006 Sep; 17(9):1441-9. PubMed ID: 16766588
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Controlling delayed vomiting: double-blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin.
    Kris MG; Gralla RJ; Tyson LB; Clark RA; Cirrincione C; Groshen S
    J Clin Oncol; 1989 Jan; 7(1):108-14. PubMed ID: 2642536
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Double-blind, dose-finding study of four intravenous doses of dexamethasone in the prevention of cisplatin-induced acute emesis. Italian Group for Antiemetic Research.
    J Clin Oncol; 1998 Sep; 16(9):2937-42. PubMed ID: 9738561
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy.
    Yeo W; Mo FK; Suen JJ; Ho WM; Chan SL; Lau W; Koh J; Yeung WK; Kwan WH; Lee KK; Mok TS; Poon AN; Lam KC; Hui EK; Zee B
    Breast Cancer Res Treat; 2009 Feb; 113(3):529-35. PubMed ID: 18327706
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A study evaluating the efficacy and tolerability of tropisetron in combination with dexamethasone in the prevention of delayed platinum-induced nausea and emesis.
    Sorbe BG; Berglind AM; Andersson H; Boman K; Högberg T; Hallgren M; Schmidt M
    Cancer; 1998 Sep; 83(5):1022-32. PubMed ID: 9731907
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Results of a compassionate-use program using intravenous ondansetron to prevent nausea and vomiting in patients receiving emetogenic cancer chemotherapy.
    Berry WR; House KW; Lee JT; Plagge PB; Meshad MW; Grapski R
    Semin Oncol; 1992 Dec; 19(6 Suppl 15):33-7. PubMed ID: 1485180
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.